Siemionow, Maria http://orcid.org/0000-0001-6372-6122
Langa, Paulina http://orcid.org/0000-0002-0334-1391
Brodowska, Sonia http://orcid.org/0000-0002-0546-0060
Kozlowska, Katarzyna http://orcid.org/0000-0002-0542-9960
Zalants, Kristina http://orcid.org/0000-0002-1914-9812
Budzynska, Katarzyna
Heydemann, Ahlke
Article History
Accepted: 26 April 2022
First Online: 19 May 2022
Change Date: 28 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12015-022-10472-3
Declarations
:
: This study was approved by the Institutional Animal Care and Use Committee (IACUC) of University of Illinois at Chicago, which is accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC).
: M.S. is CMO and shareholder of Dystrogen Therapeutics SA, the company that holds a license for DEC Therapy. The author declares a potential conflict of interest. M.S. is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO/2016/201182). AH is the adviser to Dystrogen Therapeutics.
: The authors M.S., P.L., S.B., K.K., K.Z., K.B., A.H. do not have any non-financial conflict of interest.